



# Financial results for the 3rd quarter of the year ending March 31, 2024

February 8, 2024

1. Financial results for the 3rd quarter of the year ending March 31, 2024
2. Forecast for the year ending March 31, 2024

# 3rd quarter of the year ending March 31, 2024: Summary



## Q1 to Q3 actual (YoY)

- Revenue : ¥528.9B (Up ¥72.9B YoY)
- Operating profit : ¥ 34.4B (Down ¥ 16.2B YoY)
- Profit attributable to owners of parent : ¥ 24.9B (Down ¥ 14.5B YoY)
- Revenue grew on strong sales in the Imaging Products Business, increased sales volumes of ArF lithography systems, and consolidation of SLM in the Digital Manufacturing Business.
- Operating profit down due to lower sales volumes of FPD lithography systems, the effects of reduced revenue in the Components Business, and increased expenses resulting from the SLM acquisition, etc.

## Q3 actual (YoY)

- Revenue : ¥197.7B (Up ¥30.0B YoY)
- Operating profit : ¥ 20.8B (Down ¥ 5.4B YoY)
- Profit attributable to owners of parent : ¥ 15.1B (Down ¥ 5.5B YoY)
- Revenue grew on strong sales in the Imaging Products Business, increased sales volumes of semiconductor and FPD lithography systems, and consolidation of SLM in the Digital Manufacturing Business.
- Operating profit down due to one-time costs in the Healthcare Business and increased expenses resulting from the SLM acquisition, etc.

Note: Amounts in this statement are rounded down to the hundred millions of yen.

# 1st to 3rd quarters of the year ending March 31, 2024: Financial Highlights



Billions of Yen	FY2023/3 Q1-Q3	FY2024/3 Q1-Q3	Change	
	Actual (A)	Actual (B)	Amount (B)-(A)	% (B)/(A)
<b>Revenue</b>	456.0	<b>528.9</b>	+72.9	+16.0%
<b>Operating profit</b>	50.6	<b>34.4</b>	-16.2	-32.0%
% vs Revenue	11.1%	<b>6.5%</b>	-4.6P	
<b>Profit before tax</b>	52.3	<b>36.2</b>	-16.1	-30.8%
% vs Revenue	11.5%	<b>6.8%</b>	-4.7P	
<b>Profit attributable to owners of parent</b>	39.4	<b>24.9</b>	-14.5	-36.7%
% vs Revenue	8.7%	<b>4.7%</b>	-4.0P	
<b>FCF</b>	-22.4	<b>-2.2</b>	+20.2	-
Exchange Rate: US\$	¥136	<b>¥143</b>	Impact on Revenue +17.5	
EURO	¥141	<b>¥155</b>	Impact on Operating profit +3.2	

Q3 (3 months) FCF turned positive, reducing the cumulative (9 months) FCF deficit, on improved working capital, the sale of investment securities, and the like.

# 1st to 3rd quarters of the year ending March 31, 2024: Performance by Segment



Billions of Yen		FY2023/3 Q1-Q3 Actual (A)	FY2024/3 Q1-Q3 Actual (B)	Change	
				Amount (B)-(A)	% (B)/(A)
<b>Imaging Products Business</b>	Revenue	184.4	<b>221.9</b>	+37.5	+20.4%
	Operating profit	41.2	<b>42.9</b>	+1.7	+4.2%
	% vs Revenue	22.4%	<b>19.4%</b>	-3.0P	
<b>Precision Equipment Business</b>	Revenue	133.5	<b>154.5</b>	+21.0	+15.7%
	Operating profit	14.3	<b>11.1</b>	-3.2	-22.7%
	% vs Revenue	10.8%	<b>7.2%</b>	-3.6P	
<b>Healthcare Business</b>	Revenue	72.1	<b>76.8</b>	+4.7	+6.5%
	Operating profit	7.2	<b>2.9</b>	-4.3	-59.8%
	% vs Revenue	10.1%	<b>3.8%</b>	-6.3P	
<b>Components Business</b>	Revenue	37.4	<b>32.3</b>	-5.1	-13.6%
	Operating profit	15.7	<b>11.6</b>	-4.1	-25.9%
	% vs Revenue	42.1%	<b>36.1%</b>	-6.0P	
<b>Digital Manufacturing Business</b>	Revenue	26.0	<b>40.9</b>	+14.9	+57.1%
	Operating profit	-3.8	<b>-12.8</b>	-9.0	-
	% vs Revenue	-14.7%	<b>-31.3%</b>	-16.6P	
<b>Others</b> (incl. Corporate expenses, etc.)	Revenue	2.5	<b>2.3</b>	-0.2	-7.3%
	Operating profit	-24.2	<b>-21.4</b>	+2.8	-
<b>Consolidated</b>	Revenue	456.0	<b>528.9</b>	+72.9	+16.0%
	Operating profit	50.6	<b>34.4</b>	-16.2	-32.0%
	% vs Revenue	11.1%	<b>6.5%</b>	-4.6P	

Operating profit declined YoY in all segments except for the Imaging Products Business.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# 3rd quarter of the year ending March 31, 2024: Imaging Products Business



Billions of Yen	FY2023/3 Actual		FY2024/3 Actual		Change	
	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C)-(A)	(D)-(B)
<b>Revenue</b>	69.9	184.4	<b>84.3</b>	<b>221.9</b>	+14.4	+37.5
<b>Operating profit</b>	19.0	41.2	<b>17.7</b>	<b>42.9</b>	-1.3	+1.7
% vs Revenue	27.2%	22.4%	<b>21.1%</b>	<b>19.4%</b>	-6.1P	-3.0P
<b>Digital Camera- Interchangeable Lens type (units: 1,000)</b>	210	580	<b>250</b>	<b>640</b>	+40	+60
<b>Interchangeable Lens (units: 1,000)</b>	320	930	<b>370</b>	<b>980</b>	+50	+50

- **Q1 to Q3 YoY:** Both revenue and operating profit grew. Sales volumes of mirrorless cameras, mainly the Z 8 and the Z f, and interchangeable lens of mirrorless cameras increased. ASP rose with the shift toward mid/high-end cameras. And the weaker yen helped. In Q3 (3 months), secured an operating margin of over 20%.

# 3rd quarter of the year ending March 31, 2024: Precision Equipment Business



Billions of Yen	FY2023/3 Actual		FY2024/3 Actual		Change	
	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C)-(A)	(D)-(B)
Revenue	50.2	133.5	<b>58.5</b>	<b>154.5</b>	+8.3	+21.0
Operating profit	8.1	14.3	<b>7.9</b>	<b>11.1</b>	-0.2	-3.2
% vs Revenue	16.2%	10.8%	<b>13.5%</b>	<b>7.2%</b>	-2.7P	-3.6P
FPD Lithography Systems (units)	6	19	<b>7</b>	<b>11</b>	+1	-8
Semiconductor Lithography Systems New/Refurbised (units)	6/4	14/12	<b>11/1</b>	<b>22/4</b>	+5/-3	+8/-8

- Q1 to Q3 YoY:** Revenue grew on increased sales volumes of ArF lithography systems and the booking in Q3 of 3 units of FPD lithography systems for large panels. Operating profit declined on lower volumes of FPD lithography systems sold in Q3 YTD, and lower service revenue.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# 3rd quarter of the year ending March 31, 2024: Healthcare Business



Billions of Yen	FY2023/3 Actual		FY2024/3 Actual		Change	
	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C)-(A)	(D)-(B)
<b>Revenue</b>	25.5	72.1	<b>25.6</b>	<b>76.8</b>	+0.1	+4.7
<b>Operating profit</b>	3.6	7.2	<b>0.2</b>	<b>2.9</b>	-3.4	-4.3
% vs Revenue	14.1%	10.1%	<b>0.6%</b>	<b>3.8%</b>	-13.5P	-6.3P

- Q1 to Q3 YoY:** Q3 (3 months) revenue grew on increased sales in North America and China in Life Science Solutions, despite some delays in booking sales due to parts procurement issues. The weaker yen also helped. Operating profit declined due to higher parts prices and one-time costs such as disposal and write-down of inventory, a provision (-¥1.4B) booked in Q2 in Eye Care Solutions, and survey costs related to the provision.



# 3rd quarter of the year ending March 31, 2024: Components Business



Billions of Yen	FY2023/3 Actual		FY2024/3 Actual		Change	
	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C)-(A)	(D)-(B)
<b>Revenue</b>	11.8	37.4	<b>13.6</b>	<b>32.3</b>	+1.8	-5.1
<b>Operating profit</b>	4.4	15.7	<b>5.7</b>	<b>11.6</b>	+1.3	-4.1
% vs Revenue	37.7%	42.1%	<b>42.4%</b>	<b>36.1%</b>	+4.7P	-6.0P

- **Q1 to Q3 YoY:** Revenue and operating profit declined on lower demand for optical parts due to lower utilization rates at semiconductor device makers and reduced sales of encoders and non-semiconductor customized products. Q3 (3 months) results were in line with plan.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# 3rd quarter of the year ending March 31, 2024: Digital Manufacturing Business



Billions of Yen	FY2023/3 Actual		FY2024/3 Actual		Change	
	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C)-(A)	(D)-(B)
<b>Revenue</b>	9.8	26.0	<b>14.8</b>	<b>40.9</b>	+5.0	+14.9
<b>Operating profit</b>	-1.0	-3.8	<b>-3.3</b>	<b>-12.8</b>	-2.3	-9.0
% vs Revenue	-9.5%	-14.7%	<b>-22.0%</b>	<b>-31.3%</b>	-12.5P	-16.6P

- **Q1 to Q3 YoY:** Revenues were up with the consolidation of SLM. However, operating profit was down on SLM's operating loss and intangible-asset amortization costs resulting from the SLM acquisition, as well as increased upfront investments in the Industrial Metrology Business and higher expenses due to the weaker yen. Operating loss decreased from Q2 (-¥4.8B) in Q3 due to increased sales at SLM.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

1. Financial results for the 3rd quarter of the year ending March 31, 2024

2. Forecast for the year ending March 31, 2024

# Forecast for the year ending March 31, 2024: Summary



## Revenue

- **Company total forecast: ¥705.0B** (Revised upward ¥15.0B vs. previous forecast)
  - Precision Equipment to revise upward ¥13.0B mainly due to increased sales volumes of FPD lithography systems.
  - Healthcare to revise upward ¥2.0B to reflect strong sales in Life Science Solutions and the effects of a weaker yen in Q3.

## Operating profit

- **Company total forecast: ¥ 36.0B** (Revised upward ¥2.0B vs. previous forecast)
  - Imaging Products to revise upward ¥1.0B to reflect the effects of a weaker yen in Q3.
  - Precision Equipment to revise upward ¥4.0B mainly due to increased revenues in the FPD Lithography Business.
  - Healthcare to revise downward ¥3.0B on one-time costs, etc.

## Profit attributable to owners of parent

- **Company total forecast: ¥ 27.0B** (Unchanged from previous forecast)

## Shareholder returns

- **Dividends: year-end ¥25, annual ¥50** (Unchanged from previous forecast)

## Exchange rate

- **US\$ ¥143, EURO ¥154** (Unchanged previous forecast for Q4: US\$ ¥140, EURO ¥150)

# Forecast for the year ending March 31, 2024: Financial Highlights



Billions of Yen	FY2023/3 Actual (A)	Previous Forecast (Nov. 9) (B)	New Forecast (Feb. 8) (C)	Change (C)-(A)	Change (C)-(B)
<b>Revenue</b>	628.1	690.0	<b>705.0</b>	+76.9	+15.0
<b>Operating profit</b>	54.9	34.0	<b>36.0</b>	-18.9	+2.0
% vs Revenue	8.7%	4.9%	<b>5.1%</b>	-3.6P	+0.2P
<b>Profit before tax</b>	57.0	37.0	<b>37.0</b>	-20.0	±0.0
% vs Revenue	9.1%	5.4%	<b>5.2%</b>	-3.9P	-0.2P
<b>Profit attributable to owners of parent</b>	44.9	27.0	<b>27.0</b>	-17.9	±0.0
% vs Revenue	7.2%	3.9%	<b>3.8%</b>	-3.4P	-0.1P
<b>ROE</b>	7.4%	4.2%	<b>4.2%</b>	-3.2P	±0.0P
<b>EPS</b>	¥125.46	¥77.96	<b>¥77.96</b>	-¥47.50	±¥0.00
<b>Annual Dividends</b>	¥45	¥50	<b>¥50</b>	+¥5	±¥0
Exchange Rate: US\$	¥135	¥141	<b>¥143</b>	Impact on Revenue	
				+21.6	+5.5
EURO	¥141	¥152	<b>¥154</b>	Impact on Operating profit	
				+4.1	+1.1

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.3M shares for both previous forecast (Nov. 9) and new forecast (Feb. 8).

# Forecast for the year ending March 31, 2024:


## Forecast by Segment



Billions of Yen		FY2023/3 Actual (A)	Previous Forecast (Nov. 9) (B)	New Forecast (Feb. 8) (C)	Change (C)-(A)	Change (C)-(B)
<b>Imaging Products Business</b>	Revenue	227.1	275.0	<b>275.0</b>	+47.9	±0.0
	Operating profit	42.2	43.0	<b>44.0</b>	+1.8	+1.0
	% vs Revenue	18.6%	15.6%	<b>16.0%</b>	-2.6P	+0.4P
<b>Precision Equipment Business</b>	Revenue	203.2	200.0	<b>213.0</b>	+9.8	+13.0
	Operating profit	24.5	8.0	<b>12.0</b>	-12.5	+4.0
	% vs Revenue	12.1%	4.0%	<b>5.6%</b>	-6.5P	+1.6P
<b>Healthcare Business</b>	Revenue	99.3	103.0	<b>105.0</b>	+5.7	+2.0
	Operating profit	11.5	9.5	<b>6.5</b>	-5.0	-3.0
	% vs Revenue	11.7%	9.2%	<b>6.2%</b>	-5.5P	-3.0P
<b>Components Business</b>	Revenue	53.0	47.0	<b>47.0</b>	-6.0	±0.0
	Operating profit	22.0	15.0	<b>15.0</b>	-7.0	±0.0
	% vs Revenue	41.6%	31.9%	<b>31.9%</b>	-9.7P	±0.0P
<b>Digital Manufacturing Business</b>	Revenue	42.0	62.0	<b>62.0</b>	+20.0	±0.0
	Operating profit	-10.1	-13.0	<b>-13.0</b>	-2.9	±0.0
	% vs Revenue	-24.1%	-21.0%	<b>-21.0%</b>	+3.1P	±0.0P
<b>Others</b> (incl. Corporate expenses, etc.)	Revenue	3.2	3.0	<b>3.0</b>	-0.2	±0.0
	Operating profit	-35.3	-28.5	<b>-28.5</b>	+6.8	±0.0
<b>Consolidated</b>	Revenue	628.1	690.0	<b>705.0</b>	+76.9	+15.0
	Operating profit	54.9	34.0	<b>36.0</b>	-18.9	+2.0
	% vs Revenue	8.7%	4.9%	<b>5.1%</b>	-3.6P	+0.2P

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# Forecast for the year ending March 31, 2024: Imaging Products Business



- Revenue: Unchanged from previous forecast**  
**(Up ¥47.9B YoY)**

- DCIL market expansion driven mainly by China.
- Nikon's new products (the Z 8 and the Z f) are selling well.
- Nikon has advanced its shift to mirrorless cameras and interchangeable lenses for mirrorless cameras.
- Revenue to rise YoY on the weaker yen and higher ASP driven by the shift towards mid/high-end cameras.

- Operating Profit: Up ¥1.0B vs. previous forecast**  
**(Up ¥1.8B YoY)**

- Revising upward ¥1.0B vs. previous forecast to reflect the weaker yen in Q3.
- We expect operating profit to grow YoY as higher sales volumes in DCIL and interchangeable lens, higher ASP, and the weaker yen outweigh higher parts procurement prices and increased sales promotion expenses.


## Digital Camera-Interchangeable Lens type (units: 1,000)

Market Scale	5,810	6,300	6,100
Nikon	700	800	800

## Interchangeable Lens (units:1,000)

Market Scale	9,400	10,000	9,800
Nikon	1,160	1,250	1,250

# Forecast for the year ending March 31, 2024: Precision Equipment Business



- Revenue: Up ¥13.0B vs. previous forecast**  
**(Up ¥9.8B YoY)**

- Revising upward ¥13.0B vs. previous forecast mainly due to increased sales volumes of FPD lithography systems for large panels.
- We expect revenue to grow YoY in the overall Precision Equipment Business as higher sales volumes in mainly ArF lithography systems outweighs a substantial decline in FPD lithography system sales volumes driven by delays in customer capex.

- Operating Profit: Up ¥4.0B vs. previous forecast**  
**(Down ¥12.5B YoY)**

- Revising upward ¥4.0B vs. previous forecast mainly due to increased sales volumes of FPD lithography systems.
- We expect operating profit for the overall Precision Equipment Business to decline YoY on lower sales volumes of FPD lithography systems and lower service revenue in the Semiconductor Lithography Business.

### FPD Lithography Systems (units)

Market Scale (CY22/23)	79	45	46
Nikon	29	13	16


### Semiconductor Lithography Systems (New/Refurbished, units)

Market Scale (CY22/23)	480	430	520
Nikon	27/18	30/16	30/12

Note: FY2023/3 results have been re-stated to reflect segmentation changes.



# Forecast for the year ending March 31, 2024: Healthcare Business




- **Revenue: Up ¥2.0B vs. previous forecast**  
**(Up ¥5.7B YoY)**

- Revising upward ¥2.0B vs. previous forecast to reflect increased sales of Life Science Solutions in China and the rest of Asia, and the weaker yen in Q3.
- In Life Science Solutions, we expect sales expansion mainly in North America and China on development of the private sector market and strengthening of drug discovery support and solutions.
- In Eye Care Solutions, we expect revenue to be flat YoY despite stable growth in retinal diagnostic imaging systems market because the effects of last year's major deals will disappear.

- **Operating Profit: Down ¥3.0B vs. previous forecast**  
**(Down ¥5.0B YoY)**

- Revising downward ¥3.0B on one-time costs such as disposal and write-down of inventory and survey costs related to a provision booked in Q2 in Eye Care Solutions.

# Forecast for the year ending March 31, 2024: Components Business



- **Revenue: Unchanged from previous forecast**

**(Down ¥6.0B YoY)**

- There are some signs of a recovery in the semiconductor market. However, forecasts remain unchanged as customer demand has not recovered yet.
- Lower utilization rates at semiconductor device makers will continue to impact demand for optical parts, and production adjustments and postponed investments by customers will continue to impact EUV related components and optical components.


- **Operating profit: Unchanged from previous forecast**

**(Down ¥7.0B YoY)**

- As mentioned above, there is no change in customer demand for our products, and forecasts remain unchanged.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# Forecast for the year ending March 31, 2024: Digital Manufacturing Business



- **Revenue: Unchanged from previous forecast (Up ¥20.0B YoY)**

- The Industrial Metrology Business revenue to grow on expanded sales of video measuring systems and X-ray and CT systems, etc.
- Total segment revenue to reach ¥62.0B with the full-year contribution to the Advanced Manufacturing (ADM) Business from SLM, which was acquired last fiscal year.

- **Operating Profit: Unchanged from previous forecast (Down ¥2.9B YoY)**

- The Industrial Metrology Business profit to decline YoY due to upfront investments and a one-time spike in materials costs, despite profit growth from increased sales.
- We expect operating loss to expand YoY in ADM due to SLM's operating loss and intangible-asset amortization costs over the full year, and upfront investments aimed at strengthening the business base.
- The total Digital Manufacturing Business will make an operating loss.

<Reference>





















Estimated intangible-asset amortization costs resulting from the SLM acquisition: ¥3.9B (full year)

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# Reference Data

# Business segments and major products



Segments	Description	Major products				
<b>Imaging Products Business</b>	Digital camera-interchangeable lens type Interchangeable lens Compact DSC	 Mirrorless Camera [Z 8]	 Mirrorless Camera [Z f]	 [NIKKOR] Lens	 [NIKKOR Z 135mm f/1.8 S Plena]	
<b>Precision Equipment Business</b>	FPD lithography system Semiconductor lithography system Alignment station Measuring & inspection system	 FPD Lithography System [FX-88S]	 ArF Immersion Scanner [NSR-S636E]	 Alignment Station [Litho Booster]	 Automatic Macro Inspection System [AMI-5700]	
<b>Healthcare Business</b>	Biological microscope Retinal diagnostic imaging system Contract Cell Manufacturing business	 Confocal Microscope System [AX/AX R]	 Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT [Silverstone]	 Contract Cell Manufacturing		
<b>Components Business</b>	EUV related component Optical parts, Optical components Encoders and Actuators Photomask substrate for FPD	 Optical Parts	 Optical Components	 Multi-turn Absolute Encoder [MAR-M50A]	 Intelligent actuator units [C3 eMotion]	 Photomask Substrates for FPD
<b>Digital Manufacturing Business</b>	Metal 3D printer Optical processing machine Contract material processing Measuring instrument X-ray system Industrial microscopy	 Metal 3D Printer [NXG XII 600]	 Optical Processing Machine [Lasermeister 102A]	 Video Measuring System [NEXIV VMZ-S Series]	 Laser Radar Measuring System [APDIS Series]	

# 3rd quarter of the year ending March 31, 2024: Financial Highlights



Billions of Yen	FY2023/3 Q3	FY2024/3 Q3	Change	
	Actual (A)	Actual (B)	Amount (B)-(A)	% (B)/(A)
<b>Revenue</b>	167.7	<b>197.7</b>	+30.0	+17.8%
<b>Operating profit</b>	26.2	<b>20.8</b>	-5.4	-20.6%
% vs Revenue	15.6%	<b>10.5%</b>	-5.1P	
<b>Profit before tax</b>	26.3	<b>21.0</b>	-5.3	-20.3%
% vs Revenue	15.7%	<b>10.6%</b>	-5.1P	
<b>Profit attributable to owners of parent</b>	20.6	<b>15.1</b>	-5.5	-26.3%
% vs Revenue	12.3%	<b>7.7%</b>	-4.6P	
<b>FCF</b>	-3.4	<b>23.7</b>	+27.1	-
Exchange Rate: US\$	¥141	<b>¥148</b>	Impact on Revenue +7.1	
EURO	¥144	<b>¥159</b>	Impact on Operating profit +1.4	

FCF turned positive on improved working capital, the sale of investment securities, and the like.

# 3rd quarter of the year ending March 31, 2024: Performance by Segment



Billions of Yen		FY2023/3 Q3 Actual (A)	FY2024/3 Q3 Actual (B)	Change	
				Amount (B)-(A)	% (B)/(A)
<b>Imaging Products Business</b>	Revenue	69.9	<b>84.3</b>	+14.4	+20.7%
	Operating profit	19.0	<b>17.7</b>	-1.3	-6.5%
	% vs Revenue	27.2%	<b>21.1%</b>	-6.1P	
<b>Precision Equipment Business</b>	Revenue	50.2	<b>58.5</b>	+8.3	+16.6%
	Operating profit	8.1	<b>7.9</b>	-0.2	-3.1%
	% vs Revenue	16.2%	<b>13.5%</b>	-2.7P	
<b>Healthcare Business</b>	Revenue	25.5	<b>25.6</b>	+0.1	+0.3%
	Operating profit	3.6	<b>0.2</b>	-3.4	-95.4%
	% vs Revenue	14.1%	<b>0.6%</b>	-13.5P	
<b>Components Business</b>	Revenue	11.8	<b>13.6</b>	+1.8	+15.3%
	Operating profit	4.4	<b>5.7</b>	+1.3	+29.6%
	% vs Revenue	37.7%	<b>42.4%</b>	+4.7P	
<b>Digital Manufacturing Business</b>	Revenue	9.8	<b>14.8</b>	+5.0	+51.6%
	Operating profit	-1.0	<b>-3.3</b>	-2.3	-
	% vs Revenue	-9.5%	<b>-22.0%</b>	-12.5P	
<b>Others</b> (incl. Corporate expenses, etc.)	Revenue	0.8	<b>0.9</b>	+0.1	+21.2%
	Operating profit	-8.0	<b>-7.5</b>	+0.5	-
<b>Consolidated</b>	Revenue	167.7	<b>197.7</b>	+30.0	+17.8%
	Operating profit	26.2	<b>20.8</b>	-5.4	-20.6%
	% vs Revenue	15.6%	<b>10.5%</b>	-5.1P	

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

# Forecast for the year ending March 31, 2024: Financial Highlights



Billions of Yen	FY2021/3	FY2022/3	FY2023/3			FY2024/3 Forecast		
	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
<b>Revenue</b>	451.2	539.6	288.3	339.8	628.1	<b>331.2</b>	<b>373.8</b>	<b>705.0</b>
<b>Operating profit</b> % vs Revenue	-56.2 -12.5%	49.9 9.3%	24.4 8.5%	30.5 9.0%	54.9 8.7%	<b>13.6</b> <b>4.1%</b>	<b>22.4</b> <b>6.0%</b>	<b>36.0</b> <b>5.1%</b>
<b>Profit before tax</b> % vs Revenue	-45.3 -10.0%	57.0 10.6%	26.0 9.0%	31.0 9.1%	57.0 9.1%	<b>15.2</b> <b>4.6%</b>	<b>21.8</b> <b>5.8%</b>	<b>37.0</b> <b>5.2%</b>
<b>Profit attributable to owners of parent</b> % vs Revenue	-34.4 -7.6%	42.6 7.9%	18.8 6.5%	26.1 7.7%	44.9 7.2%	<b>9.8</b> <b>3.0%</b>	<b>17.2</b> <b>4.6%</b>	<b>27.0</b> <b>3.8%</b>
<b>ROE</b>	-6.4%	7.5%		7.4%			<b>4.2%</b>	
<b>EPS</b>	-¥93.96	¥116.23		¥125.46			<b>¥77.96</b>	
<b>Annual Dividends</b>	¥20	¥40		¥45			<b>¥50</b>	
<b>FCF</b>	22.9	30.9		-112.1			-	
Exchange Rate: US\$	¥106	¥112	¥134	¥137	¥135	<b>¥141</b>	<b>¥144</b>	<b>¥143</b>
EURO	¥124	¥131	¥139	¥143	¥141	<b>¥153</b>	<b>¥155</b>	<b>¥154</b>

Note: The number of issued shares assumed for EPS forecast calculation: approx. 346.3M shares



# Forecast for the year ending March 31, 2024: Financial Highlights (Changes from Previous Forecast)



	Previous Forecast (Nov. 9) (A)			New Forecast (Feb. 8) (B)			Change (B)-(A)		
	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Billions of Yen									
<b>Revenue</b>	331.2	358.8	690.0	<b>331.2</b>	<b>373.8</b>	<b>705.0</b>	±0.0	+15.0	+15.0
<b>Operating profit</b>	13.6	20.4	34.0	<b>13.6</b>	<b>22.4</b>	<b>36.0</b>	±0.0	+2.0	+2.0
% vs Revenue	4.1%	5.7%	4.9%	<b>4.1%</b>	<b>6.0%</b>	<b>5.1%</b>	±0.0P	+0.3P	+0.2P
<b>Profit before tax</b>	15.2	21.8	37.0	<b>15.2</b>	<b>21.8</b>	<b>37.0</b>	±0.0	±0.0	±0.0
% vs Revenue	4.6%	6.1%	5.4%	<b>4.6%</b>	<b>5.8%</b>	<b>5.2%</b>	±0.0P	-0.3P	-0.2P
<b>Profit attributable to owners of parent</b>	9.8	17.2	27.0	<b>9.8</b>	<b>17.2</b>	<b>27.0</b>	±0.0	±0.0	±0.0
% vs Revenue	3.0%	4.8%	3.9%	<b>3.0%</b>	<b>4.6%</b>	<b>3.8%</b>	±0.0P	-0.2P	-0.1P
<b>ROE</b>	4.2%			<b>4.2%</b>			±0.0P		
<b>EPS</b>	¥77.96			<b>¥77.96</b>			±¥0.00		
<b>Annual Dividends</b>	¥50			<b>¥50</b>			±¥0		
Exchange Rate: US\$	¥141	¥140	¥141	<b>¥141</b>	<b>¥144</b>	<b>¥143</b>	±¥0	+¥4	+¥2
EURO	¥153	¥150	¥152	<b>¥153</b>	<b>¥155</b>	<b>¥154</b>	±¥0	+¥5	+¥2

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.3M shares for both previous forecast (Nov. 9) and new forecast (Feb. 8).

# Forecast for the year ending March 31, 2024:

## Forecast by Segment



Billions of Yen		FY2023/3			FY2024/3 Forecast		
		1H	2H	Full Year	1H	2H	Full Year
<b>Imaging Products Business</b>	Revenue	114.5	112.6	227.1	<b>137.6</b>	<b>137.4</b>	<b>275.0</b>
	Operating profit	22.2	20.0	42.2	<b>25.2</b>	<b>18.8</b>	<b>44.0</b>
<b>Precision Equipment Business</b>	Revenue	83.3	119.9	203.2	<b>96.0</b>	<b>117.0</b>	<b>213.0</b>
	Operating profit	6.2	18.3	24.5	<b>3.2</b>	<b>8.8</b>	<b>12.0</b>
<b>Healthcare Business</b>	Revenue	46.6	52.7	99.3	<b>51.2</b>	<b>53.8</b>	<b>105.0</b>
	Operating profit	3.6	7.9	11.5	<b>2.7</b>	<b>3.8</b>	<b>6.5</b>
<b>Components Business</b>	Revenue	25.6	27.4	53.0	<b>18.7</b>	<b>28.3</b>	<b>47.0</b>
	Operating profit	11.3	10.7	22.0	<b>5.9</b>	<b>9.1</b>	<b>15.0</b>
<b>Digital Manufacturing Business</b>	Revenue	16.2	25.8	42.0	<b>26.1</b>	<b>35.9</b>	<b>62.0</b>
	Operating profit	-2.8	-7.3	-10.1	<b>-9.5</b>	<b>-3.5</b>	<b>-13.0</b>
<b>Others</b>	Revenue	1.7	1.5	3.2	<b>1.4</b>	<b>1.6</b>	<b>3.0</b>
	Operating profit	1.0	1.6	2.6	<b>0.1</b>	<b>3.9</b>	<b>4.0</b>
<b>Corporate expenses, etc.</b>	Operating profit	-17.2	-20.8	-38.0	<b>-14.1</b>	<b>-18.4</b>	<b>-32.5</b>
	Broken out: Expense related to investment in growth	-10.1	-11.6	-21.7	<b>-10.2</b>	<b>-9.8</b>	<b>-20.0</b>
	Broken out: Expense for administration department	-5.8	-7.7	-13.5	<b>-6.8</b>	<b>-9.2</b>	<b>-16.0</b>
	Broken out: Elimination of intersegment transactions	-1.2	-1.5	-2.7	<b>2.9</b>	<b>0.6</b>	<b>3.5</b>
<b>Consolidated</b>	Revenue	288.3	339.8	628.1	<b>331.2</b>	<b>373.8</b>	<b>705.0</b>
	Operating profit	24.4	30.5	54.9	<b>13.6</b>	<b>22.4</b>	<b>36.0</b>

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

"Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

"Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.

# Forecast for the year ending March 31, 2024: Forecast by Segment (Changes from Previous Forecast)



Billions of Yen		Previous Forecast (Nov. 9) (A)			New Forecast (Feb. 8) (B)			Change (B)-(A)		
		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue	137.6	137.4	275.0	<b>137.6</b>	<b>137.4</b>	<b>275.0</b>	±0.0	±0.0	±0.0
	Operating profit	25.2	17.8	43.0	<b>25.2</b>	<b>18.8</b>	<b>44.0</b>	±0.0	+1.0	+1.0
Precision Equipment Business	Revenue	96.0	104.0	200.0	<b>96.0</b>	<b>117.0</b>	<b>213.0</b>	±0.0	+13.0	+13.0
	Operating profit	3.2	4.8	8.0	<b>3.2</b>	<b>8.8</b>	<b>12.0</b>	±0.0	+4.0	+4.0
Healthcare Business	Revenue	51.2	51.8	103.0	<b>51.2</b>	<b>53.8</b>	<b>105.0</b>	±0.0	+2.0	+2.0
	Operating profit	2.7	6.8	9.5	<b>2.7</b>	<b>3.8</b>	<b>6.5</b>	±0.0	-3.0	-3.0
Components Business	Revenue	18.7	28.3	47.0	<b>18.7</b>	<b>28.3</b>	<b>47.0</b>	±0.0	±0.0	±0.0
	Operating profit	5.9	9.1	15.0	<b>5.9</b>	<b>9.1</b>	<b>15.0</b>	±0.0	±0.0	±0.0
Digital Manufacturing Business	Revenue	26.1	35.9	62.0	<b>26.1</b>	<b>35.9</b>	<b>62.0</b>	±0.0	±0.0	±0.0
	Operating profit	-9.5	-3.5	-13.0	<b>-9.5</b>	<b>-3.5</b>	<b>-13.0</b>	±0.0	±0.0	±0.0
Others	Revenue	1.4	1.6	3.0	<b>1.4</b>	<b>1.6</b>	<b>3.0</b>	±0.0	±0.0	±0.0
	Operating profit	0.1	3.9	4.0	<b>0.1</b>	<b>3.9</b>	<b>4.0</b>	±0.0	±0.0	±0.0
Corporate expenses, etc.	Operating profit	-14.1	-18.4	-32.5	<b>-14.1</b>	<b>-18.4</b>	<b>-32.5</b>	±0.0	±0.0	±0.0
	Broken out: Expense related to investment in growth	-10.2	-9.8	-20.0	<b>-10.2</b>	<b>-9.8</b>	<b>-20.0</b>	±0.0	±0.0	±0.0
	Broken out: Expense for administration department	-6.8	-9.2	-16.0	<b>-6.8</b>	<b>-9.2</b>	<b>-16.0</b>	±0.0	±0.0	±0.0
	Broken out: Elimination of intersegment transactions	2.9	0.6	3.5	<b>2.9</b>	<b>0.6</b>	<b>3.5</b>	±0.0	±0.0	±0.0
Consolidated	Revenue	331.2	358.8	690.0	<b>331.2</b>	<b>373.8</b>	<b>705.0</b>	±0.0	+15.0	+15.0
	Operating profit	13.6	20.4	34.0	<b>13.6</b>	<b>22.4</b>	<b>36.0</b>	±0.0	+2.0	+2.0

Note: "Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

"Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.

# 3rd quarter of the year ending March 31, 2024: Quarterly Performance by Segment



Billions of Yen		FY2023/3				FY2024/3		
		Q1	Q2	Q3	Q4	Q1	Q2	Q3
<b>Imaging Products Business</b>	Revenue	61.2	53.3	69.9	42.7	74.4	63.2	<b>84.3</b>
	Operating profit	13.6	8.6	19.0	1.0	15.3	9.9	<b>17.7</b>
<b>Precision Equipment Business</b>	Revenue	41.4	41.9	50.2	69.7	37.3	58.7	<b>58.5</b>
	Operating profit	3.9	2.3	8.1	10.2	-3.6	6.8	<b>7.9</b>
<b>Healthcare Business</b>	Revenue	21.7	24.9	25.5	27.2	25.2	26.0	<b>25.6</b>
	Operating profit	0.8	2.8	3.6	4.3	1.8	0.9	<b>0.2</b>
<b>Components Business</b>	Revenue	12.8	12.8	11.8	15.6	8.4	10.3	<b>13.6</b>
	Operating profit	5.9	5.4	4.4	6.3	2.4	3.5	<b>5.7</b>
<b>Digital Manufacturing Business</b>	Revenue	7.4	8.8	9.8	16.0	11.9	14.2	<b>14.8</b>
	Operating profit	-0.9	-1.9	-1.0	-6.3	-4.7	-4.8	<b>-3.3</b>
<b>Others</b>	Revenue	0.9	0.8	0.8	0.7	0.6	0.8	<b>0.9</b>
	Operating profit	0.7	0.3	0.0	1.6	-0.0	0.1	<b>1.7</b>
<b>Corporate expenses, etc.</b>	Operating profit	-8.7	-8.5	-8.1	-12.7	-7.8	-6.3	<b>-9.2</b>
	Broken out: Expense related to investment in growth	-5.0	-5.1	-5.6	-6.0	-5.1	-5.1	<b>-5.1</b>
	Broken out: Expense for administration department	-2.7	-3.1	-3.3	-4.4	-3.4	-3.4	<b>-3.5</b>
	Broken out: Elimination of intersegment transactions	-0.9	-0.3	0.8	-2.3	0.7	2.2	<b>-0.6</b>
<b>Consolidated</b>	Revenue	145.6	142.7	167.7	172.1	158.1	173.1	<b>197.7</b>
	Operating profit	15.3	9.1	26.2	4.3	3.2	10.4	<b>20.8</b>

Note: FY2023/3 results have been re-stated to reflect segmentation changes.


"Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

"Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.


# 3rd quarter of the year ending March 31, 2024: Financial Position



## ASSET



## LIABILITIES/EQUITY




Note: Equity ratio is the ratio of equity attributable to owners of parent to total assets.  
Cash and cash equivalents excludes time deposits with maturities of three months or more.


# Capital Expenditures, Depreciation & Amortization, and Inventories



## CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION



## BREAKDOWN OF INVENTORIES



Note: Capital expenditures include right-of-use assets.

Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination.


Inventories of FY2023/3 results have been re-stated to reflect segmentation changes.

# 1st to 3rd quarters of the year ending March 31, 2024: Revenue Breakdown




## BY SEGMENT

Billions of Yen



## BY REGION

Billions of Yen




Note: The outside and inside circles show the breakdown of FY2024/3 Q1-Q3 revenue of ¥528.9B and FY2023/3 Q1-Q3 revenue of ¥456.0B, respectively. FY2023/3 results have been re-stated to reflect segmentation changes.


# Forecast for the year ending March 31, 2024: R&D Expenditures



## R&D EXPENDITURES



## R&D EXPENDITURES BREAKDOWN




Note: R&D expenditures includes capitalization of some development expenditures.

Due to segment revision from FY2024/3, the financial figures for FY2023/3 are displayed according to the reorganized display.



# Cash Flow History




Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

# Imaging Products Business: Sales Units




**SALES IN UNITS BY PRODUCT CATEGORY**




# Forecast for the year ending March 31, 2024: Precision Equipment Business Sales Units



**FPD LITHOGRAPHY SYSTEMS SALES  
BY GENERATION**



**SEMICONDUCTOR LITHOGRAPHY  
SYSTEMS SALES BY TECHNOLOGY  
(INCL. REFURBISHED)**




Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".  
The unit sales of new semiconductor lithography systems are 38 units in FY2020/3, 23 units in FY2021/3, 17 units in FY2022/3, 27 units in FY2023/3, and 30 units (forecast) in FY2024/3.

# Precision Equipment Business: Sales Units




**FPD LITHOGRAPHY SYSTEMS SALES IN UNITS BY GENERATION**



# Precision Equipment Business: Sales Units



## SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".

# Forecast for the year ending March 31, 2024: Foreign Exchange Impact



	Exchange Rate	Financial Impact from Fluctuation by 1 yen	
	FY2024/3 Forecast for Q4	Revenue Q4	Operating Profit Q4
US \$	¥140	Approx. ¥0.4billion	Approx. ¥0.1billion
EURO	¥150	Approx. ¥0.2billion	

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and Euro.

# Revision of reporting business segments (From FY2024/3)



Old Segment	Business Unit (BU)			Business Unit (BU)		New Segment	
Imaging Products	Imaging BU			Imaging BU		Imaging Products	
Precision Equipment	FPD Lithography BU		→	Precision Equipment Group	FPD Lithography BU	Precision Equipment	
	Semiconductor Lithography BU				Semiconductor Lithography BU		
Healthcare	Healthcare BU			Healthcare BU		Healthcare	
Components	Customized Products BU			Customized Products BU		Components	
	Glass BU			Glass BU			
	Digital Solutions BU	Optical components, etc.		→	Digital Solutions BU		
		Material processing (incl. Morf3D)			Industrial Metrology BU		
Industrial Metrology and Others	Industrial Metrology BU		→	Advanced Manufacturing BU		Digital Manufacturing	
	Others			Others*			
Corporate expenses, etc.	SLM		→	Headquarters division of the parent company		Corporate expenses, etc.	
	Next Generation Project Division			Next Generation Project Division			

Departments and subsidiaries in the Material Processing Business have been consolidated under the Advanced Manufacturing BU and combined with the Industrial Metrology BU to make up the Digital Manufacturing Business segment (aligns with Medium-Term Management Plan business domain).

\* From FY2024/3, domestic production subsidiaries under the Precision Equipment Business have been transferred to the Production Division included under the Others segment

# Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.



